Research and development - proposal log no. RC190267, a nanotechnology-enabled biosynthetic whole-blood surrogate for hemostatic resuscitation.
Ended Definitive Contract Awarded Last action
- Contract number
- W81XWH20C0144
- Awardee
-
Haima Therapeutics LLC UEI JKZPL4NA9V21
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $1,623,731
Award facts
- Opportunity
-
- DoD Combat Readiness - Rapid Development and Translational Research Award Special Notice · W81XWH19SCRRP · Posted Sep 12, 2019
- Contract value 100% obligated
- $1,623,731.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541720 Research and Development in the Social Sciences and Humanities
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Basic Research
- Pricing
- Cost No Fee
- Place of performance
- Cleveland, OH 44106, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,623,731 |
About this award
Haima Therapeutics LLC was awarded a $1.6 million definitive cost-no-fee contract by the Department of the Army Medical Command to conduct applied research and development in response to the Congressionally Directed Medical Research Programs Fiscal Year 2019 Combat Readiness-Medical Research Program Rapid Development and Translational Research Award Broad Agency Announcement. Specifically, the prime contractor will perform work on a nanotechnology-enabled biosynthetic whole-blood surrogate for hemostatic resuscitation under Proposal Log No. RC190267. The research and development effort will take place in Cleveland, Ohio over a three-year period concluding in December 2023. No subcontractors or set-aside designations were identified. The contract award aligns with the Department of Defense's focus on improving combat readiness and population health through the Medical Research Program's Rapid Development and Translational Research Award initiative.
Quick answers
Who was awarded contract W81XWH20C0144?
W81XWH20C0144 was awarded to Haima Therapeutics LLC by Medical Command (Department of the Army) on September 30, 2020.
How much is contract W81XWH20C0144 worth?
The government has obligated $1,623,731 on W81XWH20C0144.
Was contract W81XWH20C0144 competed?
The extent of competition for W81XWH20C0144 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award